Pembrolizumab Combos Miss Primary Endpoints in Liver, Prostate Cancer Trials
The LEAP-002 study evaluated pembrolizumab plus lenvatinib in patients with uHCC; the KEYNOTE-921 study evaluated pembrolizumab plus docetaxel in patients with mCRPC.
Prostate And Other Male Cancers
Prevalence of CRC Screening Remains Low in Those Aged 50 to 54
Increase in screening differed by age, with 19.4 percent increase for those aged 50 to 54 and 31.6 percent increase for those aged 70 to 75
Enzalutamide Active in Low-, Intermediate-Risk Prostate Cancer
Significant reduction seen in risk of prostate cancer progression for enzalutamide plus AS versus active surveillance alone
Higher Dairy Intake May Up Risk for Prostate Cancer
However, association does not hold for nondairy calcium intake
Darolutamide Plus Docetaxel Gets Priority Review for Metastatic Hormone-Sensitive Prostate Cancer
The sNDA is supported by data from the phase 3 ARASENS trial, which included1306 patients with mHSPC.
Camcevi Now Available for Advanced Prostate Cancer Treatment
Camcevi is a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate, a gonadotropin-releasing hormone agonist.
Pluvicto Approved for PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
Pluvicto is a radioligand therapeutic agent containing the active moiety, lutetium-177, which binds to PSMA, a transmembrane protein that is expressed in prostate cancer.
Merck Halts Trial Evaluating Combo Therapy for Metastatic Castration-Resistant Prostate Cancer
Following a planned interim analysis, the decision to halt the trial was made after a review of data by an independent Data Monitoring Committee.
Spironolactone Use Not Linked to Increased Risk for Cancer
No significant associations seen for spironolactone with risk for breast, ovarian, bladder, kidney, gastric, esophageal cancers
Niraparib With Abiraterone + Prednisone Improves Outcomes in HRR BM+ Metastatic Castration Resistant Prostate Cancer
The phase 3 MAGNITUDE study assessed niraparib in combination with abiraterone acetate plus prednisone in patients with mCRPC with or without alterations in homologous recombination repair associated genes.
